Top
Summary
All studies
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
Peer-reviewed
All outcomes

Feedback
Analgesics⏵
Antiandrogens⏵
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins⏵

Other
Feedback
Home
Top
All ensitrelvir studies
 
Feedback
Home
c19early.org COVID-19 treatment researchEnsitrelvirEnsitrelvir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta
Home Adoption Other Treatments

Outcomes in COVID-19 ensitrelvir studies

Home
Tweet
Share
@CovidAnalysis
StudiesStudies
Adoption
FeedbackFeedback
All studies   Hospitalization   Serious outcomes   Recovery   Viral clearance   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 26% 3 1,450 Improvement, Studies, Patients Relative Risk Hospitalization -1% 1 1,195 Recovery 10% 2 1,376 Viral clearance 38% 3 1,417 RCTs 26% 3 1,450 Peer-reviewed 9% 1 227 Early 26% 3 1,450 Ensitrelvir for COVID-19 c19early.org Oct 2023 Favorsensitrelvir Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mukae (DB RCT) 45% 0.55 [0.37-0.81] viral load 14 (n) 14 (n) Improvement, RR [CI] Treatment Control Mukae (DB RCT) 9% 0.91 [0.76-1.08] improv. 116 (n) 111 (n) SCORPIO-SR Yotsuyan.. (DB RCT) -1% 1.01 [0.06-16.1] hosp. 1/595 1/600 Tau​2​ = 0.08, I​2​ = 63.0%, p = 0.17 Early treatment 26% 0.74 [0.48-1.14] 1/725 1/725 26% lower risk All studies 26% 0.74 [0.48-1.14] 1/725 1/725 26% lower risk 3 ensitrelvir COVID-19 studies c19early.org October 2023 Tau​2​ = 0.08, I​2​ = 63.0%, p = 0.17 Effect extraction pre-specified(most serious outcome) Favors ensitrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ SCORPIO-SR Yotsuyan.. (DB RCT) -1% 1.01 [0.06-16.1] hosp. 1/595 1/600 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Early treatment -1% 1.01 [0.06-16.1] 1/595 1/600 1% higher risk All studies -1% 1.01 [0.06-16.1] 1/595 1/600 1% higher risk 1 ensitrelvir COVID-19 hospitalization result c19early.org October 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Favors ensitrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ SCORPIO-SR Yotsuyan.. (DB RCT) -1% 1.01 [0.06-16.1] hosp. 1/595 1/600 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Early treatment -1% 1.01 [0.06-16.1] 1/595 1/600 1% higher risk All studies -1% 1.01 [0.06-16.1] 1/595 1/600 1% higher risk 1 ensitrelvir COVID-19 serious outcome c19early.org October 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors ensitrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mukae (DB RCT) 9% 0.91 [0.76-1.08] improv. 116 (n) 111 (n) Improvement, RR [CI] Treatment Control SCORPIO-SR Yotsuyan.. (DB RCT) 11% 0.89 [0.71-1.11] recov. time 577 (n) 572 (n) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.13 Early treatment 10% 0.90 [0.78-1.03] 0/693 0/683 10% lower risk All studies 10% 0.90 [0.78-1.03] 0/693 0/683 10% lower risk 2 ensitrelvir COVID-19 recovery results c19early.org October 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.13 Favors ensitrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mukae (DB RCT) 45% 0.55 [0.37-0.81] viral load 14 (n) 14 (n) Improvement, RR [CI] Treatment Control Mukae (DB RCT) 32% 0.68 [0.56-0.82] viral time 113 (n) 108 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 49% 0.51 [0.34-0.76] viral load 579 (n) 589 (n) Tau​2​ = 0.00, I​2​ = 0.7%, p < 0.0001 Early treatment 38% 0.62 [0.53-0.73] 0/706 0/711 38% lower risk All studies 38% 0.62 [0.53-0.73] 0/706 0/711 38% lower risk 3 ensitrelvir COVID-19 viral clearance results c19early.org October 2023 Tau​2​ = 0.00, I​2​ = 0.7%, p < 0.0001 Favors ensitrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mukae (DB RCT) 45% 0.55 [0.37-0.81] viral load 14 (n) 14 (n) Improvement, RR [CI] Treatment Control Mukae (DB RCT) 9% 0.91 [0.76-1.08] improv. 116 (n) 111 (n) SCORPIO-SR Yotsuyan.. (DB RCT) -1% 1.01 [0.06-16.1] hosp. 1/595 1/600 Tau​2​ = 0.08, I​2​ = 63.0%, p = 0.17 Early treatment 26% 0.74 [0.48-1.14] 1/725 1/725 26% lower risk All studies 26% 0.74 [0.48-1.14] 1/725 1/725 26% lower risk 3 ensitrelvir COVID-19 Randomized Controlled Trials c19early.org October 2023 Tau​2​ = 0.08, I​2​ = 63.0%, p = 0.17 Effect extraction pre-specified(most serious outcome) Favors ensitrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mukae (DB RCT) 9% 0.91 [0.76-1.08] improv. 116 (n) 111 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.28 Early treatment 9% 0.91 [0.76-1.08] 0/116 0/111 9% lower risk All studies 9% 0.91 [0.76-1.08] 0/116 0/111 9% lower risk 1 ensitrelvir COVID-19 peer reviewed studies c19early.org October 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.28 Effect extraction pre-specified(most serious outcome) Favors ensitrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mukae (DB RCT) 45% 0.55 [0.37-0.81] viral load 14 (n) 14 (n) Improvement, RR [CI] Treatment Control Mukae (DB RCT) 36% 0.64 [0.41-1.00] viral load 15 (n) 14 (n) Mukae (DB RCT) 45% 0.55 [0.34-0.90] viral time 15 (n) 14 (n) Mukae (DB RCT) 44% 0.56 [0.35-0.92] viral time 13 (n) 14 (n) Mukae (DB RCT) 54% 0.46 [0.05-4.38] viral+ 1/12 2/11 Mukae (DB RCT) -10% 1.10 [0.22-5.51] viral+ 3/15 2/11 Mukae (DB RCT) 80% 0.20 [0.01-3.80] viral+ 0/13 2/13 Mukae (DB RCT) 54% 0.46 [0.05-4.53] viral+ 1/14 2/13 Mukae (DB RCT) 54% 0.46 [0.10-2.12] viral+ 2/14 4/13 Mukae (DB RCT) 90% 0.10 [0.01-0.85] viral+ 0/15 4/13 Mukae (DB RCT) 80% 0.20 [0.05-0.75] viral+ 2/14 10/14 Mukae (DB RCT) 63% 0.37 [0.15-0.92] viral+ 4/15 10/14 Mukae (DB RCT) 9% 0.91 [0.59-1.40] viral+ 10/14 11/14 Mukae (DB RCT) -10% 1.10 [0.79-1.55] viral+ 13/15 11/14 Mukae (DB RCT) 9% 0.91 [0.76-1.08] improv. 116 (n) 111 (n) Mukae (DB RCT) 17% 0.83 [0.69-0.99] improv. 114 (n) 111 (n) Mukae (DB RCT) 32% 0.68 [0.56-0.82] viral time 113 (n) 108 (n) Mukae (DB RCT) 44% 0.56 [0.42-0.75] viral time 113 (n) 108 (n) SCORPIO-SR Yotsuyan.. (DB RCT) -1% 1.01 [0.06-16.1] hosp. 1/595 1/600 SCORPIO-SR Yotsuyan.. (DB RCT) 67% 0.33 [0.01-8.15] hosp. 0/603 1/600 SCORPIO-SR Yotsuyan.. (DB RCT) 11% 0.89 [0.71-1.11] recov. time 577 (n) 572 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 10% 0.90 [0.68-1.19] recov. time 582 (n) 572 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 18% 0.82 [0.67-1.00] recov. time 330 (n) 321 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 19% 0.81 [0.67-0.98] recov. time 336 (n) 321 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 13% 0.87 [0.65-1.17] recov. time 577 (n) 572 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 10% 0.90 [0.49-1.68] recov. time 582 (n) 572 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 13% 0.87 [0.74-1.02] recov. time 330 (n) 321 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 16% 0.84 [0.70-1.01] recov. time 336 (n) 321 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 49% 0.51 [0.34-0.76] viral load 579 (n) 589 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 49% 0.51 [0.34-0.76] viral load 592 (n) 589 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 59% 0.41 [0.24-0.69] viral load 330 (n) 321 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 59% 0.41 [0.24-0.69] viral load 336 (n) 321 (n) Ensitrelvir COVID-19 outcomes c19early.org October 2023 Favors ensitrelvir Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Tweet
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0